Dr. Reddy’s Laboratories Ltd. reported a rise in second quarter profit to INR 14.37 billion, with earnings per share increasing to INR 17.25. Revenues also grew to INR 88.05 billion, driven by growth in key markets. However, the North America Generics segment faced challenges from price erosion and reduced lenalidomide sales. The Consumer Healthcare portfolio in Nicotine Replacement Therapy contributed positively to overall performance. Visit rttnews.com for more earnings news and calendar updates.

Read more at Nasdaq: Dr. Reddy’s Laboratories Q2 Profit Rises